Waverley Pharma Inc (WAVE) - Total Assets
Based on the latest financial reports, Waverley Pharma Inc (WAVE) holds total assets worth CA$1.27 Million CAD (≈ $921.59K USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Waverley Pharma Inc (WAVE) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Waverley Pharma Inc - Total Assets Trend (2015–2024)
This chart illustrates how Waverley Pharma Inc's total assets have evolved over time, based on quarterly financial data. See Waverley Pharma Inc shareholders equity for net asset value and shareholders' equity analysis.
Waverley Pharma Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Waverley Pharma Inc's total assets of CA$1.27 Million consist of 35.7% current assets and 64.3% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 11.5% |
| Accounts Receivable | CA$53.06K | 2.6% |
| Inventory | CA$261.49K | 12.8% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$397.94K | 19.5% |
| Goodwill | CA$223.56K | 10.9% |
Asset Composition Trend (2015–2024)
This chart illustrates how Waverley Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Waverley Pharma Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Waverley Pharma Inc's current assets represent 35.7% of total assets in 2024, a decrease from 100.0% in 2015.
- Cash Position: Cash and equivalents constituted 11.5% of total assets in 2024, down from 100.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 19.5% of total assets.
Waverley Pharma Inc Competitors by Total Assets
Key competitors of Waverley Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥28.15 Billion |
|
INVENTIVA ADS/1 O.N.
F:6IVA
|
Germany | €249.51 Million |
|
CorMedix Inc
NASDAQ:CRMD
|
USA | $826.14 Million |
Waverley Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.11 | 0.13 | 1.53 |
| Quick Ratio | 0.04 | 0.09 | 1.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-3.05 Million | CA$-3.11 Million | CA$588.41K |
Waverley Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Waverley Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.91 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | 114.8% |
| Total Assets | CA$2.05 Million |
| Market Capitalization | $540.00K USD |
Valuation Analysis
Below Book Valuation: The market values Waverley Pharma Inc's assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Waverley Pharma Inc's assets grew by 114.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Waverley Pharma Inc (2015–2024)
The table below shows the annual total assets of Waverley Pharma Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$2.05 Million ≈ $1.48 Million |
+114.83% |
| 2023-12-31 | CA$952.29K ≈ $688.87K |
-64.56% |
| 2022-12-31 | CA$2.69 Million ≈ $1.94 Million |
-27.05% |
| 2021-12-31 | CA$3.68 Million ≈ $2.66 Million |
+5.50% |
| 2020-12-31 | CA$3.49 Million ≈ $2.53 Million |
-20.53% |
| 2019-12-31 | CA$4.39 Million ≈ $3.18 Million |
-16.10% |
| 2018-12-31 | CA$5.24 Million ≈ $3.79 Million |
-21.35% |
| 2017-12-31 | CA$6.66 Million ≈ $4.82 Million |
+6657768.00% |
| 2016-12-31 | CA$100.00 ≈ $72.34 |
0.00% |
| 2015-12-31 | CA$100.00 ≈ $72.34 |
-- |
About Waverley Pharma Inc
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.